NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis $8.13 -0.03 (-0.38%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Addex Therapeutics Stock (NASDAQ:ADXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Addex Therapeutics alerts:Sign Up Key Stats Today's Range$8.00▼$8.0050-Day Range$6.51▼$9.0052-Week Range$6.51▼$13.27Volume405 shsAverage Volume92,798 shsMarket Capitalization$8.62 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingBuy Company OverviewAddex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Read More… Addex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreADXN MarketRank™: Addex Therapeutics scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAddex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAddex Therapeutics has received no research coverage in the past 90 days.Read more about Addex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -23.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -23.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.24% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently decreased by 44.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.24% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently decreased by 44.44%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.78 News SentimentAddex Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Addex Therapeutics this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.14% of the stock of Addex Therapeutics is held by institutions.Read more about Addex Therapeutics' insider trading history. Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXN Stock News HeadlinesAddex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Highlights: Strategic Spinout and Financial ...April 26 at 2:09 AM | gurufocus.comQ4 2024 Addex Therapeutics Ltd Earnings Call TranscriptApril 26 at 12:25 AM | gurufocus.comThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behind all the chaos you've seen play out in the global economy in 2025. This curse has nothing to do with astrology or anything metaphorical. In fact, it's studied at the highest levels of finance and academia ... and VP Vance even questioned Jerome Powell about it. It's a wild money story you could soon hear everywhere. Only one investigative journalist is telling the story here.April 28, 2025 | Stansberry Research (Ad)Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call TranscriptApril 25 at 5:41 PM | seekingalpha.comAddex Therapeutics: Addex Reports Full Year 2024 Financial Results and Provides Corporate UpdateApril 25 at 5:04 AM | finanznachrichten.deAddex Reports Full Year 2024 Financial Results and Provides Corporate UpdateApril 25 at 1:00 AM | globenewswire.comAddex Therapeutics Ltd American Depositary Shares (ADXN)April 23, 2025 | nasdaq.comAddex Therapeutics regains rights to ADX71149April 17, 2025 | markets.businessinsider.comSee More Headlines ADXN Stock Analysis - Frequently Asked Questions How have ADXN shares performed this year? Addex Therapeutics' stock was trading at $7.00 on January 1st, 2025. Since then, ADXN shares have increased by 16.1% and is now trading at $8.1290. View the best growth stocks for 2025 here. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) issued its quarterly earnings data on Friday, November, 22nd. The company reported ($2.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by $1.37. Addex Therapeutics had a net margin of 850.30% and a negative trailing twelve-month return on equity of 112.43%. Read the conference call transcript. When did Addex Therapeutics' stock split? Addex Therapeutics's stock reverse split on the morning of Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Addex Therapeutics' major shareholders? Top institutional investors of Addex Therapeutics include GAMMA Investing LLC (0.83%). How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL). Company Calendar Last Earnings11/22/2024Today4/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXN CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+286.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,760,000.00 Net Margins850.30% Pretax Margin-1,106.55% Return on Equity-112.43% Return on Assets-77.95% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.59 Sales & Book Value Annual Sales$556,045.00 Price / Sales14.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book6.47Miscellaneous Outstanding Shares1,060,000Free Float901,000Market Cap$8.23 million OptionableNot Optionable Beta1.60 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ADXN) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.